Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLCHIREN study of colchicine for secondary cardiovascular prevention and renal progression in moderate chronic kidney disease
2023-505868-11-00Phase 3Authorised
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Jan 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in chronic kidney disease (CKD) and cardiac morbidity, sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoints: Composite major vascular event incidence and Composite cardiovascular and peripheral vasculopathy incidence. Planned start Jan 2025; status: authorised.
02
Drugs
colchicine
03
Conditions
chronic kidney disease (CKD)cardiac morbidity
Beyond the preview
Go deeper on 2023-505868-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505868-11-00.